Laurus Labs (LAURUSLABS) Stock Overview
Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
LAURUSLABS Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Laurus Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,019.00 |
| 52 Week High | ₹1,141.00 |
| 52 Week Low | ₹512.35 |
| Beta | 0.24 |
| 1 Month Change | 1.31% |
| 3 Month Change | 4.17% |
| 1 Year Change | 95.42% |
| 3 Year Change | 221.55% |
| 5 Year Change | 191.02% |
| Change since IPO | 960.57% |
Recent News & Updates
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Jan 28
Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
Jan 25Recent updates
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Jan 28Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
Jan 25Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Oct 30With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Oct 19Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Aug 31Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%
Jul 20Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings
Jun 11Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet
May 19Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 27Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar
Apr 07
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Shareholder Returns
| LAURUSLABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.8% | 0.5% | 0.3% |
| 1Y | 95.4% | 5.5% | 10.9% |
Return vs Industry: LAURUSLABS exceeded the Indian Pharmaceuticals industry which returned 5.5% over the past year.
Return vs Market: LAURUSLABS exceeded the Indian Market which returned 10.9% over the past year.
Price Volatility
| LAURUSLABS volatility | |
|---|---|
| LAURUSLABS Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: LAURUSLABS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LAURUSLABS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6,167 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products.
Laurus Labs Limited Fundamentals Summary
| LAURUSLABS fundamental statistics | |
|---|---|
| Market cap | ₹550.11b |
| Earnings (TTM) | ₹8.43b |
| Revenue (TTM) | ₹67.22b |
Is LAURUSLABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAURUSLABS income statement (TTM) | |
|---|---|
| Revenue | ₹67.22b |
| Cost of Revenue | ₹28.89b |
| Gross Profit | ₹38.33b |
| Other Expenses | ₹29.90b |
| Earnings | ₹8.43b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.62 |
| Gross Margin | 57.02% |
| Net Profit Margin | 12.55% |
| Debt/Equity Ratio | 44.8% |
How did LAURUSLABS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/21 09:01 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laurus Labs Limited is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| null null | Antique Stockbroking Ltd. |
| Vijayaraghavan Swaminathan | Avendus Spark |